Delivery Order SPE2DB22D2007-SPE2DB25FJ3VA
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,474.88 to AmerisourceBergen Drug Corp for the supply of Dexcom G7 sensors. This firm fixed price, non-competitive delivery order was issued on August 8, 2025, with an ultimate completion date of August 11, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's substantial role as a federal medical supply provider,...
- The Defense Logistics Agency awarded a delivery order valued at $4,124.80 to AmerisourceBergen Drug Corp for Dexcom G7 continuous glucose monitoring sensors. This firm fixed price delivery order, effective through August 12, 2025, represents a competitively awarded, non-set-aside procurement issued on August 11, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. This...
- The Defense Logistics Agency awarded a $2,280.80 delivery order to AmerisourceBergen Drug Corp for Dexcom G7 sensors, with an ultimate completion date of August 8, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $1,031.20 to AmerisourceBergen Drug Corp for Dexcom G7 sensors on July 30, 2025, with completion scheduled for July 31, 2025. This firm fixed price contract represents a non-competitive, non-set-aside award for continuous glucose monitoring devices to support federal medical supply needs. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Dexcom G7 sensors on August 5, 2025, with a ceiling value of $1,260.46. This firm fixed-price delivery order, which is not set aside for small business or other categories, is scheduled for completion by August 6, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract represents a child award under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,036.08 to AmerisourceBergen Drug Corp for Dexcom G7 sensors, with an ultimate completion date of August 8, 2025. This firm fixed-price contract, issued on August 7, 2025, is a non-set-aside award issued under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical (SPE2DX). The sensors will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, which serves as...
- The Defense Logistics Agency awarded a delivery order valued at $1,106.94 to AmerisourceBergen Drug Corp for Dexcom G7 continuous glucose monitoring sensors. The contract is a firm fixed price delivery order with no set-aside designation, issued on August 18, 2025, with an ultimate completion date of August 19, 2025. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency has awarded a delivery order to AmerisourceBergen Drug Corp for Dexcom G7 continuous glucose monitoring sensors valued at $2,845.71. This firm fixed-price contract, executed on August 22, 2025, with an ultimate completion date of August 25, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The award...
- The Defense Logistics Agency awarded a delivery order valued at $1,295.99 to AmerisourceBergen Drug Corp for Dexcom G7 sensors on August 12, 2025, with a completion date of August 13, 2025. This firm fixed price delivery order represents a competitive award with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Dexcom G7 sensors are continuous glucose monitoring devices used for diabetes management, supporting the...
- The Defense Logistics Agency awarded a delivery order valued at $4,871.27 to AmerisourceBergen Drug Corp for Dexcom G7 continuous glucose monitoring sensors. This firm fixed-price, competitively awarded contract was finalized on August 14, 2025, with an ultimate completion date of August 15, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ3VADelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,062.40 to AmerisourceBergen Drug Corp for Dexcom G7 continuous glucose monitoring sensors. This firm fixed-price delivery order, issued on August 11, 2025, with a completion date of August 12, 2025, represents a non-competitive set-aside award. The sensors will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, supporting the agency's medical supply chain operations for federal healthcare beneficiaries, including military personnel and veterans. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. This prime vendor contract serves as a comprehensive pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications and medical devices globally to support military healthcare programs. The company's established relationship with DLA demonstrates its capability as a critical pharmaceutical distributor, positioning it to fulfill specialized medical device needs such as continuous glucose monitoring systems for diabetes management within the federal healthcare system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.1k | 8/11/25 |